Compare BHST & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHST | KZIA |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | Canada | Australia |
| Employees | 87 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.2M | 93.2M |
| IPO Year | N/A | 2002 |
| Metric | BHST | KZIA |
|---|---|---|
| Price | $4.28 | $7.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $12.00 | ★ $17.67 |
| AVG Volume (30 Days) | 17.5K | ★ 113.5K |
| Earning Date | 05-14-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $146.27 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.10 | $0.64 |
| 52 Week High | $12.80 | $17.40 |
| Indicator | BHST | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 47.82 |
| Support Level | $4.19 | $6.44 |
| Resistance Level | $4.96 | $8.05 |
| Average True Range (ATR) | 0.21 | 0.69 |
| MACD | 0.03 | -0.08 |
| Stochastic Oscillator | 33.33 | 26.63 |
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.